GLP-1
GLP-1
GLP-1
Orforglipron (Foundayo) 2026: The First Oral GLP-1 Pill for Weight Loss — Complete Guide
The FDA approved orforglipron (Foundayo) in April 2026 — the first oral small-molecule GLP-1 agonist for weight management. No needles, no food restrictions, and significantly lower cost than injectable alternatives.
GLP-1
Retatrutide 2026: The Triple Agonist Rewriting Weight Loss Science
GLP-1
Semaglutide 2026 Complete Guide: Ozempic vs. Wegovy, Dosing, SELECT Trial & Comparison to Tirzepatide
Ozempic and Wegovy contain the same molecule but serve different purposes. Here's the 2026 guide to semaglutide: dosing, the SELECT cardiovascular trial, the new oral pill, and how it compares to tirzepatide.
GLP-1
Tirzepatide 2026 Complete Guide: Dosing, Benefits, Side Effects & Comparison to Semaglutide
Tirzepatide (Zepbound/Mounjaro) delivered 47% greater weight loss than semaglutide in the SURMOUNT-5 trial. Here's the complete 2026 guide to dosing, benefits, side effects, and what compounding restrictions mean for patients.
GLP-1
Orforglipron (Foundayo) 2026: The First Oral GLP-1 Pill Without Food Restrictions — Complete Guide
A once-daily pill you can take any time — with food, without food, with coffee, without water restrictions — has arrived. Orforglipron (brand name Foundayo), developed by Eli Lilly, is the world's first oral non-peptide GLP-1 receptor agonist. The FDA approved it in April 2026, and it represents a genuine
GLP-1
Tirzepatide 2026: The Complete Guide to Dosing, Weight Loss, and How It Compares to Semaglutide
The landmark SURMOUNT-5 trial proved tirzepatide produces 47% more weight loss than semaglutide. Here's everything you need to know about dosing, side effects, cardiovascular outcomes, and the 2026 legal status of compounded tirzepatide.
GLP-1
Pemvidutide 2026: The GLP-1/Glucagon Dual Agonist Rewriting MASH and Weight Loss Treatment
Pemvidutide earned FDA Breakthrough Therapy Designation for MASH in January 2026, with 59.1% biopsy-confirmed MASH resolution and best-in-class 21.9% lean mass loss during weight reduction.
GLP-1
Gonadorelin: The TRT Peptide That Keeps Your Testosterone Axis Alive
GLP-1
Retatrutide: The Triple-Receptor Agonist GLP-1 Guide (2026 Phase 3 Data)
GLP-1
Retatrutide: The Triple Agonist GLP-1 That Outperforms Everything
Retatrutide achieved 28.7% weight loss in Phase 3 trials — the highest ever recorded. Here's how the GLP-1/GIP/glucagon triple agonist works, what the data shows, and when it could reach patients.
GLP-1
Semaglutide for Fatty Liver Disease (MASH/NAFLD): Complete Guide to the ESSENCE Trial and FDA Approval
Fatty liver disease has quietly become one of the most common chronic liver conditions in the world — and for decades, patients had no approved treatments beyond lifestyle changes. That changed in 2024 and 2025, as two landmark drug approvals gave clinicians new weapons against a disease affecting tens of millions